Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report.
Bleomycin is a commonly used anticancer agent; in particular, it is an important component of multidrug regimens for germ cell tumors. The limiting toxicity of bleomycin is represented by pulmonary interstitial fibrosis; mucocutaneous side effects are common, but usually harmless. We describe a case of a young girl who developed Stevens-Johnson syndrome following the administration of bleomycin in a three-drug regimen containing vinblastine and cisplatin, for an ovarian immature teratoma. The severe dermatologic toxicity was kept under control, but a rapidly evolving respiratory insufficiency due to lung fibrosis developed soon thereafter and caused the patient's death.
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000150:complications / Q000473:pathology; D012131:Respiratory Insufficiency / Q000209:etiology; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced*; D013724:Teratoma / Q000188:drug therapy; D014747:Vinblastine / Q000009:adverse effects
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin